New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
12:41 EDTJNJ, ENDP, ACT, TEVAChicago files lawsuit against Actavis, Endo, Janssen, Teva, Chicago Tribune says
Chicago has filed a lawsuit against Actavis (ACT), Endo Health Solutions (ENDP), Teva's (TEVA) Cephalon, Johnson & Johnson's (JNJ) Janssen Pharmaceuticals and Purdue Pharma, accusing the companies of concealing the risks associated with certain painkillers, the Chicago Tribune reports. The suit alleges the companies used "deceptive marketing practices to encourage doctors to prescribe and patients" to purchase more of these painkillers, leading to a rise in the "misuse and abuse" in the drugs. Reference Link
News For ACT;JNJ;TEVA;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 9, 2015
06:20 EDTTEVATeva bid for Mylan possible, but challenging, says Citigroup
Subscribe for More Information
06:15 EDTTEVACiti does not see much strategic sense in Mylan, Perrigo deal
Subscribe for More Information
05:49 EDTTEVAStocks with implied volatility movement; MYL TEVA
Subscribe for More Information
April 8, 2015
16:22 EDTTEVAOn The Fly: Closing Wrap
Subscribe for More Information
14:23 EDTTEVAAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTTEVAMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
12:37 EDTTEVATeva downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
09:23 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information
07:24 EDTJNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
07:16 EDTTEVAMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
April 7, 2015
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
April 6, 2015
14:34 EDTJNJDepomed price target raised to $30 from $27 at Roth Capital
Subscribe for More Information
09:36 EDTJNJActive equity options trading on open
Subscribe for More Information
06:21 EDTJNJJohnson & Johnson CEO comments on Asia expansion, WSJ reports
Subscribe for More Information
05:56 EDTTEVATeva battles possible generic Copaxone competitors, Globes reports
A citizen's petition has been filed by Teva with the FDA against possible generic competition to its MS treatment Copaxone beginning in September, Globes reports. The FDA has previously ruled that it was "too early" to discuss the matter. Reference Link
April 5, 2015
14:43 EDTACTActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use